Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.48 |
| ▸ | FNTB | P49356 | 8/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970877 | 1.00 | FNTA (0.48) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL8749214 | 0.97 | FNTA (0.46) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL8749207 | 0.97 | FNTA (0.46) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL5970446 | 0.94 | LMNA (0.51) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL935514 | 0.94 | LMNA (0.51) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL30578362 | 0.93 | DPP4 (0.45) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL29592643 | 0.93 | FNTA (0.48) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL30591103 | 0.93 | FNTA (0.48) | FNTAFNTBPGGT1BLMNADPP4 | |
| SCHEMBL31433270 | 0.92 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL29939156 | 0.92 | FNTA (0.43) | FNTAFNTBPGGT1BLMNADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116987148-B | Synthesis process of acetyl hexapeptide-8 | 山东济肽生物科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-116987148-A | Synthesis process of acetyl hexapeptide-8 | 山东济肽生物科技有限公司 | 2023-11-03 | — | — | CN | claimed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | claimed |
| CN-113845586-B | Method for liquid-phase synthesis of acetyl hexapeptide-8 | 汉肽生物医药集团有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | claimed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-115850487-B | Anti-human CD137 antibody, nucleic acid molecule and application | 首都医科大学附属北京胸科医院 | 2025-02-25 | — | — | CN | disclosed |
| CN-116041517-B | Anti-human CD137 antibody and application thereof | 首都医科大学附属北京胸科医院 | 2025-02-25 | — | — | CN | disclosed |
| CN-113929749-B | Sixteen peptide compound and preparation method thereof | 陕西未来多肽生物科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116987148-B | Synthesis process of acetyl hexapeptide-8 | 山东济肽生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| US-20060217321-A1 | Compositions to improve tic disorders | TAIYOKAGAKU CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
| US-20050037453-A1 | Peptide-forming enzyme gene, peptide-forming enzyme, and peptide producing method | AJINOMOTO CO. INC (JP) | 2005-02-17 | — | — | US | disclosed |
| CN-1558947-A | Gene of peptide-producing enzyme, and process for producing dipeptide | ֮����ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| EP-1411116-A1 | PEPTIDE SYNTHASE GENE, PEPTIDE SYNTHASE AND PROCESS FOR PRODUCING DIPEPTIDE | Ajinomoto Co., Inc. (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-0571198-B1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5559092-A | HAIR GROWTH, GLUTAMINE DIPEPTIDE | CHESEBROUGH-POND'S USA CO. DIVISION OF CONOPCO, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0571198-A1 | Cosmetic composition containing hair-growth promoter | UNILEVER PLC (GB) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | FNTA 1639/4885FNTB 208/4885PGGT1B 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.